XTX Topco Ltd Makes New Investment in Immunome, Inc. (NASDAQ:IMNM)

XTX Topco Ltd purchased a new stake in Immunome, Inc. (NASDAQ:IMNM) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 24,823 shares of the company’s stock, valued at approximately $363,000.

Other large investors have also modified their holdings of the company. Quest Partners LLC purchased a new position in shares of Immunome during the 2nd quarter worth approximately $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Immunome during the second quarter worth $97,000. Arizona State Retirement System grew its stake in shares of Immunome by 9.2% in the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after buying an additional 918 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Immunome in the 3rd quarter valued at $219,000. Finally, AQR Capital Management LLC lifted its stake in Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock worth $194,000 after acquiring an additional 4,129 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on IMNM. Stephens assumed coverage on shares of Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price target on the stock. Piper Sandler dropped their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $28.83.

Immunome Trading Down 1.1 %

Immunome stock opened at $12.44 on Tuesday. The stock has a market cap of $776.47 million, a P/E ratio of -1.53 and a beta of 1.83. The company has a fifty day simple moving average of $12.22 and a 200-day simple moving average of $13.43. Immunome, Inc. has a 12-month low of $7.48 and a 12-month high of $30.96.

Insiders Place Their Bets

In related news, insider Robert Lechleider acquired 15,805 shares of the firm’s stock in a transaction on Thursday, November 21st. The stock was bought at an average price of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the purchase, the insider now directly owns 15,805 shares of the company’s stock, valued at approximately $149,831.40. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Clay B. Siegall bought 66,057 shares of the business’s stock in a transaction dated Thursday, November 21st. The shares were purchased at an average price of $9.54 per share, for a total transaction of $630,183.78. Following the transaction, the chief executive officer now directly owns 485,693 shares of the company’s stock, valued at approximately $4,633,511.22. This represents a 15.74 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 102,862 shares of company stock valued at $978,045 in the last ninety days. Insiders own 8.60% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.